PPARA and obesity due to melanocortin 4 receptor deficiency: The current patent provided an intermediate compound in synthesizing PPAR modulating compounds like thiazolidinedione in the treatment or prevention of metabolic disorders such as obesity, hypertension, inflammatory diseases, and diabetes.